Skip to main content

Rett In The News

UMASS Chan Medical School
March 4, 2024
UMASS Chan Medical School announces the $2.3 million award from RSRT to develop genetic medicines for Rett syndrome.
January 5, 2024
ProQR, a biotech company in The Netherlands, and RSRT have initiated a collaboration to develop RNA editiing therapeutics for Rett syndrome. RSRT has made an initial $1 million award to ProQR.
January 5, 2024
Key highlights from Neurogene's update include approval to dose patient #3; clearance to initiate a trial in the UK; plans to expand the US trial to more patients and to test a higher dose; expect to share data on US trial in Q4 2024.
January 2, 2024
Anavex Life Sciences, a biotech company that has come under fire for trying to spin its clinical trial results, wants to claim partial success on a late-stage trial in kids with Rett syndrome, a rare genetic neurological disorder. However, the biotech’s own ad-hoc analysis says otherwise.